Katrin Sangkuhl

Katrin Sangkuhl

UNVERIFIED PROFILE

Are you Katrin Sangkuhl?   Register this Author

Register author
Katrin Sangkuhl

Katrin Sangkuhl

Publications by authors named "Katrin Sangkuhl"

Are you Katrin Sangkuhl?   Register this Author

33Publications

-Reads

Prediction of CYP2D6 phenotype from genotype across world populations.

Genet Med 2017 01 7;19(1):69-76. Epub 2016 Jul 7.

Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Children's Mercy-Kansas City, Kansas City, Missouri, USA.

View Article
January 2017

PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses.

Pharmacogenet Genomics 2015 Aug;25(8):416-26

aDepartment of Systems Pharmacology and Translational Therapeutics, Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania Departments of bGenetics cBioengineering, Stanford University Medical Center, Stanford University, Stanford, California, USA.

View Article
August 2015

PharmGKB summary: very important pharmacogene information for CYP4F2.

Pharmacogenet Genomics 2015 Jan;25(1):41-7

Departments of aGenetics bBioengineering, Stanford University, Stanford, California, USA.

View Article
January 2015

PharmGKB summary: gemcitabine pathway.

Pharmacogenet Genomics 2014 Nov;24(11):564-74

Departments of aGenetics bBioengineering, Stanford University, Stanford, California, USA cDepartment of Pharmacotherapy and Translational Research dCenter for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, Florida eDepartment of Molecular Pharmacology & Experimental Therapeutics, Division of Clinical Pharmacology, Mayo Clinic, Rochester, Minnesota, USA.

View Article
November 2014

PharmGKB summary: venlafaxine pathway.

Pharmacogenet Genomics 2014 Jan;24(1):62-72

Departments of aGenetics bBioengineering, Stanford University, Stanford, California, USA cInstitute of Pharmacology of Natural Products & Clinical Pharmacology, University of Ulm, Ulm dResearch Division, Federal Institute of Drugs & Medical Devices (BfArM), Bonn, Germany eDepartment of Pharmacology and Toxicology, Institute of Biomedicine, University of Oulu, Oulu, Finland.

View Article
January 2014

PharmGKB summary: mycophenolic acid pathway.

Pharmacogenet Genomics 2014 Jan;24(1):73-9

aDepartment of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota Departments of bGenetics cBioengineering, Stanford University Medical Center, Stanford University, Stanford, California, USA.

View Article
January 2014

PharmGKB summary: zidovudine pathway.

Pharmacogenet Genomics 2012 Dec;22(12):891-4

Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, Minnesota, USA.

View Article
December 2012

Using ODIN for a PharmGKB revalidation experiment.

Database (Oxford) 2012 23;2012:bas021. Epub 2012 Apr 23.

Institute of Computational Linguistics, Binzmuhlestrasse 171, 8050 Zurich, Switzerland.

View Article
June 2012

PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19.

Pharmacogenet Genomics 2012 Feb;22(2):159-65

Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, New York, USA.

View Article
February 2012

PharmGKB summary: citalopram pharmacokinetics pathway.

Pharmacogenet Genomics 2011 Nov;21(11):769-72

Department of Genetics, Stanford University, Stanford, California, USA.

View Article
November 2011

Platelet aggregation pathway.

Pharmacogenet Genomics 2011 Aug;21(8):516-21

Department of Genetics, Stanford University, Stanford, California, USA.

View Article
August 2011

PharmGKB summary: dopamine receptor D2.

Pharmacogenet Genomics 2011 Jun;21(6):350-6

Evolutionary Systems Biology, Artificial Intelligence Center, SRI International, Menlo Park, California, USA.

View Article
June 2011

PharmGKB summary: cytochrome P450, family 2, subfamily J, polypeptide 2: CYP2J2.

Pharmacogenet Genomics 2011 May;21(5):308-11

Department of Genetics, Stanford University, Stanford, CA 94305-5120, USA.

View Article
May 2011

PharmGKB: very important pharmacogene--HMGCR.

Pharmacogenet Genomics 2011 Feb;21(2):98-101

Children's Hospital Oakland Research Institute, Oakland, California, USA.

View Article
February 2011

Clopidogrel pathway.

Pharmacogenet Genomics 2010 Jul;20(7):463-5

Department of Genetics, Stanford University, Stanford, California 94305-5120, USA.

View Article
July 2010

Cytochrome P450 2C9-CYP2C9.

Pharmacogenet Genomics 2010 Apr;20(4):277-81

Center for Pharmacogenomics at Washington University, St Louis, Missouri, USA.

View Article
April 2010

Selective serotonin reuptake inhibitors pathway.

Pharmacogenet Genomics 2009 Nov;19(11):907-9

Department of Genetics, Stanford University Medical Center, Stanford, California, USA.

View Article
November 2009

Cytochrome P450 2D6.

Pharmacogenet Genomics 2009 Jul;19(7):559-62

Department of Genetics, Stanford University Medical Center, Stanford, California 94305, USA.

View Article
July 2009

PharmGKB: understanding the effects of individual genetic variants.

Drug Metab Rev 2008 ;40(4):539-51

Department of Genetics, Stanford University, Stanford, California 94305-5120, USA.

View Article
May 2009

V2 vasopressin receptor deficiency causes changes in expression and function of renal and hypothalamic components involved in electrolyte and water homeostasis.

Am J Physiol Renal Physiol 2008 Oct 20;295(4):F1177-90. Epub 2008 Aug 20.

Institute of Biochemistry, Molecular Biochemistry, Medical Faculty, University of Leipzig, Johannisallee 30, 04103 Leipzig, Germany.

View Article
October 2008

Nephrogenic diabetes insipidus, thiazide treatment and renal cell carcinoma.

Nephrol Dial Transplant 2006 Apr 19;21(4):1082-6. Epub 2006 Jan 19.

Pediatric Department, Farwania Hospital, Safat, Kuwait.

View Article
April 2006

Identification of receptors and signaling pathways for orphan bone morphogenetic protein/growth differentiation factor ligands based on genomic analyses.

J Biol Chem 2005 Sep 27;280(37):32122-32. Epub 2005 Jul 27.

Division of Reproductive Biology, Department of Obstetrics and Gynecology, Stanford University School of Medicine, California 94305-5317, USA.

View Article
September 2005

Nephrogenic diabetes insipidus caused by mutation of Tyr205: a key residue of V2 vasopressin receptor function.

Hum Mutat 2005 May;25(5):505

Institute of Biochemistry, Dept. of Molecular Biochemistry, Medical Faculty, University of Leipzig, Leipzig, Germany.

View Article
May 2005

Mutant G-protein-coupled receptors as a cause of human diseases.

Pharmacol Ther 2004 Dec;104(3):173-206

Institute of Biochemistry, Department of Molecular Biochemistry (Max-Planck-Institute Interim), Medical Faculty, University of Leipzig, Deutscher Platz 6, 04103 Leipzig, Germany.

View Article
December 2004

Aminoglycoside-mediated rescue of a disease-causing nonsense mutation in the V2 vasopressin receptor gene in vitro and in vivo.

Hum Mol Genet 2004 May 3;13(9):893-903. Epub 2004 Mar 3.

Institute of Biochemistry, Department of Molecular Biochemistry, Medical Faculty, University of Leipzig, Leipzig, Germany.

View Article
May 2004

Structural requirements for mutational lutropin/choriogonadotropin receptor activation.

J Biol Chem 2002 Dec 27;277(49):47748-55. Epub 2002 Sep 27.

Institut für Pharmakologie, Universitätsklinikum Benjamin Franklin, Freie Universität Berlin, Thielallee 69-73, D-14195 Berlin, Germany.

View Article
December 2002

Aminoglycoside pretreatment partially restores the function of truncated V(2) vasopressin receptors found in patients with nephrogenic diabetes insipidus.

J Clin Endocrinol Metab 2002 Nov;87(11):5247-57

Institut für Pharmakologie, Freie Universität Berlin, Universitätsklinikum Benjamin Franklin, Thielallee 69-73, 14195 Berlin, Germany.

View Article
November 2002